Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 67(11): 9465-9484, 2024 Jun 13.
Artigo em Inglês | MEDLINE | ID: mdl-38753983

RESUMO

Clostridioides difficile (C. difficile) is one of the leading causes of healthcare-associated infections worldwide. The increasing incidence of strains resistant to currently available therapies highlights the need for alternative treatment options with a novel mode of action. Oxazolidinones that are connected to a quinolone moiety with a pyrrolidine linker, such as compound 1, are reported to exhibit potent broadspectrum antibacterial activity. In an effort to optimize this class of compounds for the treatment of C. difficile infection (CDI), we have identified cadazolid (9), a first-in-class quinoxolidinone antibiotic, which is a potent inhibitor of C. difficile protein synthesis. In order to achieve narrow-spectrum coverage of clinically most relevant strains without affecting the gut microbiota, an emphasis was placed on abolishing activity against commensals of the intestinal microbiome while retaining good coverage of pathogenic C. difficile, including hypervirulent and epidemic strains.


Assuntos
Antibacterianos , Clostridioides difficile , Infecções por Clostridium , Testes de Sensibilidade Microbiana , Relação Estrutura-Atividade , Antibacterianos/farmacologia , Antibacterianos/química , Antibacterianos/uso terapêutico , Antibacterianos/síntese química , Clostridioides difficile/efeitos dos fármacos , Infecções por Clostridium/tratamento farmacológico , Animais , Humanos , Descoberta de Drogas , Microbioma Gastrointestinal/efeitos dos fármacos , Camundongos , Oxazolidinonas
2.
Proc Am Control Conf ; 2023: 1576-1583, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37521902

RESUMO

Modern control theory provides us with a spectrum of methods for studying the interconnection of dynamic systems using input-output properties of the interconnected subsystems. Perhaps the most advanced framework for such input-output analysis is the use of Integral Quadratic Constraints (IQCs), which considers the interconnection of a nominal linear system with an unmodelled nonlinear or uncertain subsystem with known input-output properties. Although these methods are widely used for Ordinary Differential Equations (ODEs), there have been fewer attempts to extend IQCs to infinite-dimensional systems. In this paper, we present an IQC-based framework for Partial Differential Equations (PDEs) and Delay Differential Equations (DDEs). First, we introduce infinite-dimensional signal spaces, operators, and feedback interconnections. Next, in the main result, we propose a formulation of hard IQC-based input-output stability conditions, allowing for infinite-dimensional multipliers. We then show how to test hard IQC conditions with infinite-dimensional multipliers on a nominal linear PDE or DDE system via the Partial Integral Equation (PIE) state-space representation using a sufficient version of the Kalman-Yakubovich-Popov lemma (KYP). The results are then illustrated using four example problems with uncertainty and nonlinearity.

3.
Water Sci Technol ; 84(9): 2353-2365, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34810316

RESUMO

Grey-box models, which combine the explanatory power of first-principle models with the ability to detect subtle patterns from data, are gaining increasing attention in wastewater sectors. Intuitive, simple structured but fit-for-purpose grey-box models that capture time-varying dynamics by adaptively estimating parameters are desired for process optimization and control. As an example, this study presents the identification of such a grey-box model structure and its further use by an extended Kalman filter (EKF), for the estimation of the nitrification capacity and ammonia concentrations of a typical Modified Ludzack-Ettinger (MLE) process. The EKF was implemented and evaluated in real time by interfacing Python with SUMO (Dynamita™), a widely used commercial process simulator. The EKF was able to accurately estimate the ammonia concentrations in multiple tanks when given only the concentration in one of them. In addition, the nitrification capacity of the system could be tracked in real time by the EKF, which provides intuitive information for facility managers and operators to monitor and operate the system. Finally, the realization of EKF is critical to the development of future advance control, for instance, model predictive control.


Assuntos
Amônia , Águas Residuárias
4.
J Med Chem ; 63(1): 66-87, 2020 01 09.
Artigo em Inglês | MEDLINE | ID: mdl-31804826

RESUMO

UDP-3-O-((R)-3-hydroxymyristoyl)-N-glucosamine deacetylase (LpxC) is as an attractive target for the discovery and development of novel antibacterial drugs to address the critical medical need created by multidrug resistant Gram-negative bacteria. By using a scaffold hopping approach on a known family of methylsulfone hydroxamate LpxC inhibitors, several hit series eliciting potent antibacterial activities against Enterobacteriaceae and Pseudomonas aeruginosa were identified. Subsequent hit-to-lead optimization, using cocrystal structures of inhibitors bound to Pseudomonas aeruginosa LpxC as guides, resulted in the discovery of multiple chemical series based on (i) isoindolin-1-ones, (ii) 4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-ones, and (iii) 1,2-dihydro-3H-pyrrolo[1,2-c]imidazole-3-ones. Synthetic methods, antibacterial activities and relative binding affinities, as well as physicochemical properties that allowed compound prioritization are presented. Finally, in vivo properties of lead molecules which belong to the most promising pyrrolo-imidazolone series, such as 18d, are discussed.


Assuntos
Amidoidrolases/antagonistas & inibidores , Antibacterianos/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Infecções por Escherichia coli/tratamento farmacológico , Bactérias Gram-Negativas/efeitos dos fármacos , Ácidos Hidroxâmicos/uso terapêutico , Animais , Antibacterianos/síntese química , Antibacterianos/farmacocinética , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacocinética , Escherichia coli/efeitos dos fármacos , Feminino , Ácidos Hidroxâmicos/síntese química , Ácidos Hidroxâmicos/farmacocinética , Klebsiella pneumoniae/efeitos dos fármacos , Camundongos Endogâmicos ICR , Testes de Sensibilidade Microbiana , Pseudomonas aeruginosa/efeitos dos fármacos , Pseudomonas aeruginosa/enzimologia , Pirróis/síntese química , Pirróis/farmacocinética , Pirróis/uso terapêutico
5.
J Med Chem ; 63(1): 88-102, 2020 01 09.
Artigo em Inglês | MEDLINE | ID: mdl-31804829

RESUMO

LpxC inhibitors were optimized starting from lead compounds with limited efficacy and solubility and with the goal to provide new options for the treatment of serious infections caused by Gram-negative pathogens in hospital settings. To enable the development of an aqueous formulation for intravenous administration of the drug at high dose, improvements in both solubility and antibacterial activity in vivo were prioritized early on. This lead optimization program resulted in the discovery of compounds such as 13 and 30, which exhibited high solubility and potent efficacy against Gram-negative pathogens in animal infection models.


Assuntos
Amidoidrolases/antagonistas & inibidores , Antibacterianos/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Infecções por Escherichia coli/tratamento farmacológico , Ácidos Hidroxâmicos/uso terapêutico , Administração Intravenosa , Animais , Antibacterianos/administração & dosagem , Antibacterianos/síntese química , Antibacterianos/farmacocinética , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacocinética , Bactérias Gram-Negativas/efeitos dos fármacos , Hepatócitos/metabolismo , Ácidos Hidroxâmicos/administração & dosagem , Ácidos Hidroxâmicos/síntese química , Ácidos Hidroxâmicos/farmacocinética , Camundongos , Testes de Sensibilidade Microbiana , Estrutura Molecular , Ratos , Solubilidade
6.
IEEE ASME Trans Mechatron ; 23(4): 1532-1542, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30595643

RESUMO

Optical tweezers have enabled important insights into intracellular transport through the investigation of motor proteins, with their ability to manipulate particles at the microscale, affording femto newton force resolution. Its use to realize a constant force clamp has enabled vital insights into the behavior of motor proteins under different load conditions. However, the varying nature of disturbances and the effect of thermal noise pose key challenges to force regulation. Furthermore, often the main aim of many studies is to determine the motion of the motor and the statistics related to the motion, which can be at odds with the force regulation objective. In this article, we propose a mixed objective H 2 /H ∞ optimization framework using a model-based design, that achieves the dual goals of force regulation and real time motion estimation with quantifiable guarantees. Here, we minimize the H ∞ norm for the force regulation and error in step estimation while maintaining the H 2 norm of the noise on step estimate within user specified bounds. We demonstrate the efficacy of the framework through extensive simulations and an experimental implementation using an optical tweezer setup with live samples of the motor protein 'kinesin'; where regulation of forces below 1 piconewton with errors below 10% is obtained while simultaneously providing real time estimates of motor motion.

7.
J Med Chem ; 60(9): 3755-3775, 2017 05 11.
Artigo em Inglês | MEDLINE | ID: mdl-28406299

RESUMO

Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.


Assuntos
Antibacterianos/farmacologia , Isoquinolinas/farmacologia , Animais , Antibacterianos/química , Área Sob a Curva , Descoberta de Drogas , Bactérias Gram-Negativas/efeitos dos fármacos , Meia-Vida , Ligação de Hidrogênio , Isoquinolinas/química , Isoquinolinas/farmacocinética , Isoquinolinas/uso terapêutico , Testes de Sensibilidade Microbiana , Canais de Potássio/efeitos dos fármacos , Ratos , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/microbiologia , Solubilidade , Ureia/química
8.
J Med Chem ; 60(9): 3776-3794, 2017 05 11.
Artigo em Inglês | MEDLINE | ID: mdl-28406300

RESUMO

There is an urgent unmet medical need for novel antibiotics that are effective against a broad range of bacterial species, especially multidrug resistant ones. Tetrahydropyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity against Gram-positive pathogens and no target-mediated cross-resistance with fluoroquinolones. We report our research efforts aimed at expanding the antibacterial spectrum of this class of molecules toward difficult-to-treat Gram-negative pathogens. Physicochemical properties (polarity and basicity) were considered to guide the design process. Dibasic tetrahydropyran-based compounds such as 6 and 21 are potent inhibitors of both DNA gyrase and topoisomerase IV, displaying antibacterial activities against Gram-positive and Gram-negative pathogens (Staphylococcus aureus, Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii). Compounds 6 and 21 are efficacious in clinically relevant murine infection models.


Assuntos
Antibacterianos/farmacologia , Bactérias Gram-Negativas/efeitos dos fármacos , Piranos/farmacologia , Inibidores da Topoisomerase/síntese química , Inibidores da Topoisomerase/farmacologia , Animais , Antibacterianos/efeitos adversos , Antibacterianos/síntese química , Cobaias , Humanos , Testes de Sensibilidade Microbiana , Miócitos Cardíacos/efeitos dos fármacos , Piranos/efeitos adversos , Piranos/síntese química , Inibidores da Topoisomerase/efeitos adversos
9.
Antimicrob Agents Chemother ; 60(1): 628-31, 2016 01.
Artigo em Inglês | MEDLINE | ID: mdl-26503650

RESUMO

The promotion of colonization with vancomycin-resistant enterococci (VRE) is one potential side effect during treatment of Clostridium difficile-associated diarrhea (CDAD), resulting from disturbances in gut microbiota. Cadazolid (CDZ) is an investigational antibiotic with potent in vitro activity against C. difficile and against VRE and is currently in clinical development for the treatment of CDAD. We report that CDZ treatment did not lead to intestinal VRE overgrowth in mice.


Assuntos
Antibacterianos/efeitos adversos , Clostridioides difficile/efeitos dos fármacos , Diarreia/tratamento farmacológico , Enterocolite Pseudomembranosa/tratamento farmacológico , Oxazolidinonas/farmacologia , Vancomicina/efeitos adversos , Aminoglicosídeos/farmacologia , Animais , Antibacterianos/administração & dosagem , Clostridioides difficile/crescimento & desenvolvimento , Clostridioides difficile/patogenicidade , Contagem de Colônia Microbiana , Diarreia/etiologia , Diarreia/microbiologia , Diarreia/patologia , Enterocolite Pseudomembranosa/etiologia , Enterocolite Pseudomembranosa/microbiologia , Enterocolite Pseudomembranosa/patologia , Fidaxomicina , Intestinos/efeitos dos fármacos , Intestinos/microbiologia , Intestinos/patologia , Metronidazol/farmacologia , Camundongos , Testes de Sensibilidade Microbiana , Infecções Estreptocócicas/tratamento farmacológico , Infecções Estreptocócicas/microbiologia , Infecções Estreptocócicas/patologia , Resultado do Tratamento , Vancomicina/administração & dosagem , Resistência a Vancomicina , Enterococos Resistentes à Vancomicina/efeitos dos fármacos , Enterococos Resistentes à Vancomicina/crescimento & desenvolvimento , Enterococos Resistentes à Vancomicina/patogenicidade
10.
J Med Chem ; 58(2): 927-42, 2015 Jan 22.
Artigo em Inglês | MEDLINE | ID: mdl-25494934

RESUMO

Novel antibacterial drugs that are effective against infections caused by multidrug resistant pathogens are urgently needed. In a previous report, we have shown that tetrahydropyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. During the course of our optimization program, lead compound 5 was deprioritized due to adverse findings in cardiovascular safety studies. In the effort of mitigating these findings and optimizing further the pharmacological profile of this class of compounds, we have identified a subseries of tetrahydropyran-based molecules that are potent DNA gyrase and topoisomerase IV inhibitors and display excellent antibacterial activity against Gram positive pathogens, including clinically relevant resistant isolates. One representative of this class, compound 32d, elicited only weak inhibition of hERG K(+) channels and hNaV1.5 Na(+) channels, and no effects were observed on cardiovascular parameters in anesthetized guinea pigs. In vivo efficacy in animal infection models has been demonstrated against Staphylococcus aureus and Streptococcus pneumoniae strains.


Assuntos
Antibacterianos/síntese química , Bactérias Gram-Positivas/efeitos dos fármacos , Piranos/síntese química , Inibidores da Topoisomerase II/síntese química , Animais , Antibacterianos/farmacologia , Cobaias , Hemodinâmica/efeitos dos fármacos , Humanos , Masculino , Camundongos , Testes de Sensibilidade Microbiana , Piranos/farmacologia , Ratos , Ratos Wistar , Relação Estrutura-Atividade , Inibidores da Topoisomerase II/farmacologia
11.
Antimicrob Agents Chemother ; 58(2): 892-900, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24277020

RESUMO

Clostridium difficile is a leading cause of health care-associated diarrhea with significant morbidity and mortality, and new options for the treatment of C. difficile-associated diarrhea (CDAD) are needed. Cadazolid is a new oxazolidinone-type antibiotic that is currently in clinical development for treatment of CDAD. Here, we report the in vitro and in vivo antibacterial evaluation of cadazolid against C. difficile. Cadazolid showed potent in vitro activity against C. difficile with a MIC range of 0.125 to 0.5 µg/ml, including strains resistant to linezolid and fluoroquinolones. In time-kill kinetics experiments, cadazolid showed a bactericidal effect against C. difficile isolates, with >99.9% killing in 24 h, and was more bactericidal than vancomycin. In contrast to metronidazole and vancomycin, cadazolid strongly inhibited de novo toxin A and B formation in stationary-phase cultures of toxigenic C. difficile. Cadazolid also inhibited C. difficile spore formation substantially at growth-inhibitory concentrations. In the hamster and mouse models for CDAD, cadazolid was active, conferring full protection from diarrhea and death with a potency similar to that of vancomycin. These findings support further investigations of cadazolid for the treatment of CDAD.


Assuntos
Antibacterianos/farmacologia , Clostridioides difficile/efeitos dos fármacos , Infecções por Clostridium/tratamento farmacológico , Enterocolite Pseudomembranosa/tratamento farmacológico , Oxazolidinonas/farmacologia , Esporos Bacterianos/efeitos dos fármacos , Acetamidas/farmacologia , Animais , Proteínas de Bactérias/antagonistas & inibidores , Proteínas de Bactérias/biossíntese , Toxinas Bacterianas/antagonistas & inibidores , Toxinas Bacterianas/biossíntese , Clostridioides difficile/crescimento & desenvolvimento , Clostridioides difficile/metabolismo , Infecções por Clostridium/microbiologia , Infecções por Clostridium/mortalidade , Cricetinae , Enterocolite Pseudomembranosa/microbiologia , Enterocolite Pseudomembranosa/mortalidade , Enterotoxinas/antagonistas & inibidores , Enterotoxinas/biossíntese , Feminino , Fluoroquinolonas/farmacologia , Humanos , Linezolida , Masculino , Metronidazol/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , Testes de Sensibilidade Microbiana , Esporos Bacterianos/crescimento & desenvolvimento , Análise de Sobrevida , Vancomicina/farmacologia
12.
J Med Chem ; 56(18): 7396-415, 2013 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-23968485

RESUMO

There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase-topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K(+) channel block. On the other hand, analog 49e displayed lower hERG K(+) channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.


Assuntos
Antibacterianos/síntese química , Antibacterianos/farmacologia , DNA Topoisomerases/metabolismo , Desenho de Fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Piranos/síntese química , Piranos/farmacologia , Animais , Antibacterianos/metabolismo , Antibacterianos/farmacocinética , Técnicas de Química Sintética , DNA Girase/química , DNA Girase/metabolismo , DNA Topoisomerase IV/antagonistas & inibidores , DNA Topoisomerase IV/química , DNA Topoisomerase IV/metabolismo , DNA Topoisomerases/química , Feminino , Bactérias Gram-Positivas/enzimologia , Humanos , Concentração Inibidora 50 , Camundongos , Simulação de Acoplamento Molecular , Conformação Proteica , Piranos/metabolismo , Piranos/farmacocinética , Ratos , Relação Estrutura-Atividade , Inibidores da Topoisomerase II , Inibidores da Topoisomerase/síntese química , Inibidores da Topoisomerase/metabolismo , Inibidores da Topoisomerase/farmacocinética , Inibidores da Topoisomerase/farmacologia
13.
Bioorg Med Chem Lett ; 22(21): 6705-11, 2012 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-23006603

RESUMO

A series of 2-amino-[1,8]-naphthyridine-3-carboxamides (ANCs) with potent inhibition of bacterial NAD(+)-dependent DNA ligases (LigAs) evolved from a 2,4-diaminopteridine derivative discovered by HTS. The design was guided by several highly resolved X-ray structures of our inhibitors in complex with either Streptococcus pneumoniae or Escherichia coli LigA. The structure-activity-relationship based on the ANC scaffold is discussed. The in-depth characterization of 2-amino-6-bromo-7-(trifluoromethyl)-[1,8]-naphthyridine-3-carboxamide, which displayed promising in vitro (MIC Staphylococcus aureus 1 mg/L) and in vivo anti-staphylococcal activity, is presented.


Assuntos
Antibacterianos/síntese química , Antibacterianos/farmacologia , DNA Ligases/antagonistas & inibidores , Desenho de Fármacos , Staphylococcus/efeitos dos fármacos , Animais , Antibacterianos/química , Antibacterianos/uso terapêutico , Cristalografia por Raios X , DNA Bacteriano/antagonistas & inibidores , Concentração Inibidora 50 , Camundongos , Testes de Sensibilidade Microbiana , Estrutura Molecular , Ratos , Infecções Estafilocócicas/tratamento farmacológico , Relação Estrutura-Atividade
14.
J Clin Microbiol ; 44(10): 3760-7, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17021106

RESUMO

With fluorescently labeled PNA (peptide nucleic acid) probes targeting 16S rRNA, we established a 3-h fluorescence in situ hybridization (FISH) procedure for specific visualization of members of the Mycobacterium tuberculosis complex, M. leprae, M. avium, and M. kansasii. Probe specificity was tested against a panel of 25 Mycobacterium spp. and 10 gram-positive organisms. After validation, probes were used to identify 52 mycobacterial culture isolates. Results were compared to conventional genotypic identification with amplification-based methods. All isolates (M. tuberculosis complex, n = 24; M. avium, n = 7; M. kansasii, n = 1) were correctly identified by FISH. In addition, the technique was used successfully for visualization of mycobacteria in biopsies from infected humans or animals. In conclusion, PNA-FISH is a fast and accurate tool for species-specific identification of culture-grown mycobacteria and for direct visualization of these organisms in tissue sections. It may be used successfully for both research and clinical microbiology.


Assuntos
Hibridização in Situ Fluorescente/métodos , Infecções por Mycobacterium/diagnóstico , Mycobacterium/classificação , Ácidos Nucleicos Peptídicos , Humanos , Mycobacterium/isolamento & purificação , Infecções por Mycobacterium/microbiologia , Sondas de Ácido Nucleico , Sensibilidade e Especificidade
15.
Eur J Immunol ; 36(3): 631-47, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16479545

RESUMO

A potent Th1 immune response is critical to the control of tuberculosis. The impact of an additive Th2 response on the course of disease has so far been insufficiently characterized, despite increased morbidity after co-infection with Mycobacterium tuberculosis and Th2-eliciting helminths and possible involvement of Th2 polarization in reactivation of latent tuberculosis. Here, we describe the gene expression profile of murine bone marrow-derived macrophages alternatively activated by IL-4 in response to infection with M. tuberculosis. Comparison of transcriptional profiles of infected IL-4- and IFN-gamma-activated macrophages revealed delayed and partially diminished responses to intracellular bacteria in alternatively activated macrophages, characterized by reduced exposure to nitrosative stress and increased iron availability, respectively. Alternative activation of host macrophages correlated with elevated expression of the M. tuberculosis iron storage protein bacterioferritin as well as reduced expression of the mycobactin synthesis genes mbtI and mbtJ. The extracellular matrix-remodeling enzyme matrix metalloproteinase (MMP)-12 was induced in alternatively activated macrophages in vitro, and MMP-12-expressing macrophages were abundant at late, but not early, stages of tuberculosis in murine lungs. Our findings emphasize that alternative activation deprives macrophages of control mechanisms that limit mycobacterial growth in vivo, thus supporting intracellular persistence of M. tuberculosis.


Assuntos
Células da Medula Óssea/imunologia , Regulação da Expressão Gênica/imunologia , Ativação de Macrófagos/imunologia , Macrófagos/imunologia , Mycobacterium tuberculosis/imunologia , Tuberculose Pulmonar/imunologia , Animais , Antineoplásicos/farmacologia , Proteínas de Bactérias/imunologia , Células da Medula Óssea/microbiologia , Células da Medula Óssea/patologia , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Regulação Bacteriana da Expressão Gênica/genética , Regulação Bacteriana da Expressão Gênica/imunologia , Helmintíase/imunologia , Helmintíase/patologia , Interferon gama/farmacologia , Interleucina-4/farmacologia , Ferro/imunologia , Pulmão/imunologia , Pulmão/microbiologia , Pulmão/patologia , Ativação de Macrófagos/efeitos dos fármacos , Macrófagos/microbiologia , Macrófagos/patologia , Metaloproteinase 12 da Matriz , Metaloendopeptidases/imunologia , Camundongos , Mycobacterium tuberculosis/genética , Oxazóis/imunologia , Células Th1/imunologia , Células Th2/imunologia , Tuberculose Pulmonar/genética , Tuberculose Pulmonar/patologia
16.
J Clin Invest ; 115(9): 2472-9, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16110326

RESUMO

The tuberculosis vaccine Mycobacterium bovis bacille Calmette-Guérin (BCG) was equipped with the membrane-perforating listeriolysin (Hly) of Listeria monocytogenes, which was shown to improve protection against Mycobacterium tuberculosis. Following aerosol challenge, the Hly-secreting recombinant BCG (hly+ rBCG) vaccine was shown to protect significantly better against aerosol infection with M. tuberculosis than did the parental BCG strain. The isogenic, urease C-deficient hly+ rBCG (DeltaureC hly+ rBCG) vaccine, providing an intraphagosomal pH closer to the acidic pH optimum for Hly activity, exhibited still higher vaccine efficacy than parental BCG. DeltaureC hly+ rBCG also induced profound protection against a member of the M. tuberculosis Beijing/W genotype family while parental BCG failed to do so consistently. Hly not only promoted antigen translocation into the cytoplasm but also apoptosis of infected macrophages. We concluded that superior vaccine efficacy of DeltaureC hly+ rBCG as compared with parental BCG is primarily based on improved cross-priming, which causes enhanced T cell-mediated immunity.


Assuntos
Vacina BCG , Toxinas Bacterianas/metabolismo , Proteínas de Choque Térmico/metabolismo , Listeria monocytogenes/metabolismo , Tuberculose/prevenção & controle , Adulto , Animais , Apoptose , Proteínas de Bactérias/genética , Proteínas de Bactérias/imunologia , Células Cultivadas , Criança , Proteínas Hemolisinas , Humanos , Concentração de Íons de Hidrogênio , Listeria monocytogenes/imunologia , Macrófagos/citologia , Macrófagos/metabolismo , Camundongos , Camundongos SCID , Mycobacterium tuberculosis/imunologia , Mycobacterium tuberculosis/metabolismo , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/uso terapêutico , Taxa de Sobrevida , Vacinas Sintéticas
17.
J Pathol ; 205(5): 633-40, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15776475

RESUMO

The diagnosis of mycobacterial infection depends on the Ziehl-Neelsen (ZN) stain, which detects mycobacteria because of their characteristic acid-fast cell wall composition and structure. The histological diagnosis of tuberculosis (TB) comprises various aspects: (1) sensitive detection of mycobacteria; (2) precise localization of mycobacteria in the context of granulomatous lesions; (3) 'staging' of disease according to mycobacterial spread and granulomatous tissue integrity. Thus, detection of minute numbers of acid-fast bacteria in tissue specimens is critical. The conventional ZN stain fails to identify mycobacteria in numbers less than 10(4) per ml. Hence many infections evade diagnosis. PCR is highly sensitive, but allows neither localization within tissues nor staging of mycobacterial disease, and positive findings frequently do not correlate with disease. In this study, an anti-Mycobacterium bovis bacille Calmette-Guérin polyclonal antiserum (pAbBCG) was used to improve immunostaining, which was compared to the ZN stain in histological samples. Screening of tissue samples including lungs, pleural lesions, lymph nodes, bone marrow, and skin for mycobacterial infection revealed that pAbBCG staining detects infected macrophages harbouring intracellular mycobacteria or mycobacterial material as well as free mycobacteria that are present at low abundance and not detected by the ZN stain. The positive pAbBCG staining results were confirmed either by PCR analysis of microdissected stained tissue or by culture from tissue. This immunostaining approach allows precise localization of the pathogen in infected tissue.


Assuntos
Mycobacterium tuberculosis/isolamento & purificação , Coloração e Rotulagem/métodos , Tuberculose/diagnóstico , Sítios de Ligação , Células Cultivadas , Humanos , Soros Imunes/imunologia , Hibridização in Situ Fluorescente/métodos , Microdissecção/métodos , Mycobacterium bovis/imunologia , Reação em Cadeia da Polimerase/métodos , Sensibilidade e Especificidade , Tuberculose/microbiologia , Tuberculose Pulmonar/diagnóstico , Tuberculose Pulmonar/microbiologia
18.
Tuberculosis (Edinb) ; 85(1-2): 29-38, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15687025

RESUMO

The TB Vaccine Cluster project funded by the EU Fifth Framework programme aims to provide novel vaccines against tuberculosis that are suitable for evaluation in humans. This paper describes the studies of the protective efficacy of vaccines in a guinea pig aerosol-infection model of primary tuberculosis. The objective was to conduct comparative evaluations of vaccines that had previously demonstrated efficacy in other animal models. Groups of 6 guinea pigs were immunized with vaccines provided by the relevant EU Vaccine Cluster partners. Survival over 17 or 26 weeks was used as the principal measure of vaccine efficacy following aerosol challenge with H37Rv. Counts of mycobacteria in lungs and spleens, and histopathological changes in the lungs, were also used to provide evidence of protection. A total of 24 vaccines were evaluated in 4 experiments each of a different design. A heterologous prime-boost strategy of DNA and MVA, each expressing Ag85A and a fusion protein of ESAT-6 and Ag85B in adjuvant, protected the guinea pigs to the same extent as BCG. Genetically modified BCG vaccines and boosted BCG strategies also protected guinea pigs to the same extent as BCG but not statistically significantly better. A relatively high aerosol-challenge dose and evaluation over a protracted time post-challenge allowed superior protection over BCG to be demonstrated by BCG boosted with MVA and fowl pox vectors expressing Ag85A.


Assuntos
Modelos Animais de Doenças , Vacinas contra a Tuberculose/uso terapêutico , Tuberculose/prevenção & controle , Aerossóis , Animais , Vacina BCG/uso terapêutico , Contagem de Colônia Microbiana/métodos , Avaliação Pré-Clínica de Medicamentos/métodos , União Europeia , Cobaias , Humanos , Pulmão/microbiologia , Mycobacterium tuberculosis/imunologia , Mycobacterium tuberculosis/isolamento & purificação , Baço/microbiologia , Análise de Sobrevida , Tuberculose/imunologia , Vacinas contra a Tuberculose/imunologia , Tuberculose Pulmonar/imunologia , Tuberculose Pulmonar/prevenção & controle , Vacinação/métodos
20.
J Infect Dis ; 188(9): 1326-31, 2003 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-14593589

RESUMO

Ziehl-Neelsen (ZN) staining is the key technique for diagnosis of mycobacterial infections; however, a high percentage of patients exhibit positive signs of tuberculosis, as indicated by pathology, culture of mycobacteria, and polymerase chain-reaction analysis, and yet show negative results on ZN staining. In this report we present evidence that such ZN-negative specimens represent Mycobacterium tuberculosis bacilli in a dormant state with distinct cell-wall alterations: the classical cell-wall composition-dependent ZN staining of M. tuberculosis in lung sections gradually discontinued with persistence of infection, both in mice and in human patients; in contrast, detection of mycobacteria by cell-wall composition-independent staining using a polyclonal anti-M. bovis Bacille-Calmette-Guérin serum continued with persistence of infection. These findings have important implications for diagnosis, as well as for both chemotherapy and development of vaccine strategies.'


Assuntos
Mycobacterium tuberculosis/ultraestrutura , Corantes de Rosanilina , Tuberculose/microbiologia , Animais , Vacina BCG , Proteínas de Bactérias/metabolismo , Parede Celular/metabolismo , Feminino , Humanos , Imuno-Histoquímica , Pulmão/microbiologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Mycobacterium tuberculosis/metabolismo , Coloração e Rotulagem/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...